GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect & identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, & state-of-the-art computer science & data science to enhance the scientific understanding of cancer biology, & to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, & the United Kingdom. GRAIL is a wholly-owned subsidiary of Illumina (NASDAQ:ILMN). For more information, please visit www.grail.com.